Open Access

Glaucocalyxin A alleviates lipopolysaccharide‑induced inflammation and apoptosis in pulmonary microvascular endothelial cells and permeability injury by inhibiting STAT3 signaling

  • Authors:
    • Jianwei Cao
    • Meiling Liu
    • Shufang Feng
    • Yingying Li
    • Kaijun Zheng
  • View Affiliations

  • Published online on: March 1, 2022     https://doi.org/10.3892/etm.2022.11242
  • Article Number: 313
  • Copyright: © Cao et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )
Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )


Abstract

Glaucocalyxin A (GLA), an ent‑kauranoid diterpene derived from Rabdosia japonica var. glaucocalyx, possesses antibacterial, anti‑oxidative and anti‑neuroinflammatory properties. The present study aimed to investigate the potential mechanisms underlying GLA in the pathogenesis of pneumonia. Human pulmonary microvascular endothelial cells (hPMVECs) treated with lipopolysaccharide (LPS) were treated with GLA, followed by the detection of cell viability, inflammation, apoptosis and cell permeability. Furthermore, the protein expression levels of apoptosis‑ and permeability‑associated proteins were determined using western blot analysis. Following treatment with a signal transducer and activator of transcription 3 (STAT3) activator, the protein expression levels of STAT3 and endoplasmic reticulum stress‑associated proteins were determined, to confirm whether STAT3 signaling was mediated by GLA. Lastly, the mRNA expression level of inflammatory cytokines, apoptosis and permeability injury were also determined following treatment with a STAT3 activator. The results revealed that GLA ameliorated inflammation, apoptosis and permeability injury in LPS‑induced hPMVECs. Following treatment with a STAT3 activator, the therapeutic effects of GLA on LPS‑induced hPMVECs were abrogated. In conclusion, GLA alleviated LPS‑induced inflammation, apoptosis and permeability injury in hPMVECs by inhibiting STAT3 signaling, which highlighted the potential therapeutic value of GLA in the treatment of pneumonia.
View Figures
View References

Related Articles

Journal Cover

April-2022
Volume 23 Issue 4

Print ISSN: 1792-0981
Online ISSN:1792-1015

Sign up for eToc alerts

Recommend to Library

Copy and paste a formatted citation
x
Spandidos Publications style
Cao J, Liu M, Feng S, Li Y and Zheng K: Glaucocalyxin A alleviates lipopolysaccharide‑induced inflammation and apoptosis in pulmonary microvascular endothelial cells and permeability injury by inhibiting STAT3 signaling. Exp Ther Med 23: 313, 2022
APA
Cao, J., Liu, M., Feng, S., Li, Y., & Zheng, K. (2022). Glaucocalyxin A alleviates lipopolysaccharide‑induced inflammation and apoptosis in pulmonary microvascular endothelial cells and permeability injury by inhibiting STAT3 signaling. Experimental and Therapeutic Medicine, 23, 313. https://doi.org/10.3892/etm.2022.11242
MLA
Cao, J., Liu, M., Feng, S., Li, Y., Zheng, K."Glaucocalyxin A alleviates lipopolysaccharide‑induced inflammation and apoptosis in pulmonary microvascular endothelial cells and permeability injury by inhibiting STAT3 signaling". Experimental and Therapeutic Medicine 23.4 (2022): 313.
Chicago
Cao, J., Liu, M., Feng, S., Li, Y., Zheng, K."Glaucocalyxin A alleviates lipopolysaccharide‑induced inflammation and apoptosis in pulmonary microvascular endothelial cells and permeability injury by inhibiting STAT3 signaling". Experimental and Therapeutic Medicine 23, no. 4 (2022): 313. https://doi.org/10.3892/etm.2022.11242